1.Karagiannis GS, Pastoriza JM, Wang Y et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med. 2017; 9(399).
2.Chang YS, Jalgaonkar SP, Middleton JD, Hai T. Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis. ProcNatlAcadSci U S A. 2017; 114(34): E7159–68.
3.Chang J, Bhasin SS, Bielenberg DR et al. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. Faseb J. 2019; 33(1): 114–25.
4.Butera G, Pacchiana R, Donadelli M. Autocrine mechanisms of cancer chemoresistance. Semin Cell Dev Biol. 2018; 78: 3–12.
5.Wei R, Wong J, Kwok HF. Osteopontin—a promising biomarker for cancer therapy. J Cancer. 2017; 8(12): 2173–83.
6.Hao C, Cui Y, Owen S et al. Human osteopontin: Potential clinical applications in cancer (Review). Int J Mol Med. 2017; 39(6): 1327–37.
7.Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014; 37:131–41.
8.Briones-Orta MA, Avendano-Vazquez SE, Aparicio-Bautista DI et al.Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim Biophys Acta Rev Cancer. 2017; 1868(1): 93–108.
9.Hao C, Cui Y, Hu MU et al. OPN-a splicing variant expression in non-small cell lung cancer and its effects on the bone metastatic abilities of lung cancer cells in vitro. Anticancer Res. 2017; 37(5): 2245–54.
10.Ferreira LB, Lima RT, Bastos A et al. OPNa overexpression is associated with matrix calcification in thyroid cancer cell lines. Int J Mol Sci. 2018; 19(10). pii: E2990.
11.Tilli TM, Franco VF, Robbs BK et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 2011; 9(3): 280–93.
12.Sullivan J, Blair L, Alnajar A et al. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol Histopathol. 2011; 26(7): 893–904.
13.Walaszek K, Lower EE, Ziolkowski P, Weber GF. Breast cancer risk in premalignant lesions: Osteopontin splice variants indicate prognosis. Br J Cancer. 2018; 119(10): 1259–66.
14.Ng L, Wan TM, Lam CS et al. Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. Plos One. 2015; 10(5): e126219.
15.Likui W, Hong W, Shuwen Z. Clinical significance of the upregulatedosteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg. 2010; 14(1): 74–81.
16.Qi T, Yang H, Fan X et al. Engineering of GCaMP6-based calcium indicators for nuclear calcium imaging. Zhongguo Sheng wu Hua xue yu Fen zi Sheng wu Xue bao. 2015; 31(6): 592–98.
17.Gimba E, Brum M, Nestal DMG. Full-length osteopontin and its splice variants as modulators of chemoresistance and radioresistance (Review). Int J Oncol. 2019; 54(2): 420–30.
18.Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: Dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003; 4(7): 517–29.
19.Takemoto-Kimura S, Suzuki K, Horigane SI et al. Calmodulin kinases: Essential regulators in health and disease. J Neurochem. 2017; 141(6): 808–18.
20.Wang YY, Zhao R, Zhe H. The emerging role of CaMKII in cancer.Oncotarget. 2015; 6(14): 11725–34.
21.Lev MG, Yearim A, Ast G. The alternative role of DNA methylation in splicing regulation.Trends Genet. 2015; 31(5): 274–80.
22.Buchthal B, Lau D, Weiss U et al.Nuclear calcium signaling controls methyl-CpG-binding protein 2 (MeCP2) phosphorylation on serine 421 following synaptic activity. J Biol Chem. 2012; 287(37): 30967–74.
23.Maunakea AK, Chepelev I, Cui K, Zhao K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res. 2013; 23(11): 1256–69.
24.Boudjadi S, Bernatchez G, Beaulieu JF, Carrier JC. Control of the human osteopontin promoter by ERRalpha in colorectal cancer. Am J Pathol. 2013; 183(1): 266–76.
25.Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring HarbPerspect Biol. 2016; 8(9). pii: a019505.
26.Sun XX, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment.ActaPharmacol Sin. 2015; 36(10): 1219–27.
27.Rodvold JJ, Chiu KT, Hiramatsu N et al. Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells. Sci Signal. 2017; 10(482). pii: eaah7177.
28.Sharma A, Nguyen H, Cai L, Lou H. Histone hyperacetylation and exon skipping: A calcium-mediated dynamic regulation in cardiomyocytes. Nucleus-Phila. 2015; 6(4): 273–78.
29.Razanau A, Xie J. Emerging mechanisms and consequences of calcium regulation of alternative splicing in neurons and endocrine cells. Cell Mol Life Sci. 2013; 70(23): 4527–36.
30.Luco RF, Allo M, Schor IE et al.Epigenetics in alternative pre-mRNA splicing. Cell. 2011; 144(1): 16–26.